Keros Therapeutics ( (KROS) ) has issued an announcement.
Keros Therapeutics has appointed Dr. Yung H. Chyung as the new Chief Medical Officer, effective November 1, 2024. Dr. Chyung, with a robust background in biochemical sciences and medicine from Harvard, joins Keros from Tourmaline Bio, bringing extensive expertise in the TGF-ß superfamily. His leadership is expected to be pivotal as Keros gears up for a Phase 3 clinical trial of elritercept for myelodysplastic syndromes and anticipates critical data readouts for other promising candidates in 2025.
For detailed information about KROS stock, go to TipRanks’ Stock Analysis page.
